'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 399-403

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adjuvant; Anastrozole; Aromatase inhibitor; ATAC; Early breast cancer; Postmenopausal women; Randomized clinical trial; Tamoxifen

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ACUTE DISEASE; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLLES FRACTURE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FOLLOW UP; FRACTURE; GENDER; GENERAL CONDITION IMPROVEMENT; HIP FRACTURE; HOT FLUSH; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SPINE FRACTURE; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VOMITING; WRIST FRACTURE;

EID: 0242626126     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00350-9     Document Type: Conference Paper

References (9)

1. Buzdar A.U., Jones S.E., Vogel C.L.et al. A phase III trial comparing anastrozole (1 and 10 mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer. 79:1997;730-739.
2. Jonat W W., Howell A., Blomqvist C.et al. A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer. 32A:1996;404-412.
3. Buzdar A.U., Jonat W., Howell A.et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Cancer. 83:1998;1142-1152.
4. Nabholtz J.M., Buzdar A., Pollak M., Harwin W. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. 18:2000;3758-3767.
5. The ATAC Trialists' Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet 359 (2002) 2131-2139.
6. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet 351 (1998) 1451-1467.
7. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer, Interim analysis at 4 years by Nolvadex Adjuvant Trial Organisation, Lancet 1 (8319) (1983) 257-261.
8. Nolvadex Adjuvant Trial Organisation, Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer, Analysis at 6 years by Nolvadex Adjuvant Trial Organisation, Lancet 1 (8433) (1985) 836-840.
9. Nolvadex Adjuvant Trial Organisation, Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer, Br. J. Cancer 57 (6) (1988) 608-611.